American College of Gastroenterology

Researchers test 3 different doses of mirikizumab in both biologic experienced and naïve Crohn’s disease patients.

An expert discusses a study assessing the effects of low compliance to eosinophilic esophagitis therapies among pediatric patients.

Ustekinumab resulted in a reduction of both stool frequency and rectal bleeding for ulcerative colitis patients.

New research shows patients with chronic liver disease admitted for influenza had an increased risk of disease severity but not a higher odds of mortality.

More than half of the patient population achieved a defined response at both day 14 and week 6.

Research shows dupilumab remains effective in EoE for up to 2 years.

A new study presented at ACG shows vedolizumab to be superior to adalimumab in maintaining early disease control in patients with moderate-to-severe ulcerative colitis.

In data presented at ACG, investigators found a link between sex, lower BMI, and the development of irritable bowel syndrome in patients following a c. diff infection.

In a poster presented during ACG, investigators show data from a long-term extension of the UNIFI trial.

Patients with chronic pancreatitis can exhibit dependence on chronic opioid therapy prior to receiving total pancreatectomy with islet autotransplantation.

Isolation as a result of suspected C. Diff can take a significant financial toll on the healthcare system, thus it is necessary to determine appropriate factors that can predict CDI.

Millie Long, MD, MPH, FACG, associate professor of medicine at the University of North Carolina, Chapel Hill, discusses the exciting research she saw at ACG 2019.

Miguel Regueiro, MD and George Khoudari, MD, both of the Cleveland Clinic, discuss predictors of colectomies for IBD-patients.

William Sandborn, MD, chief of the division of gastroenterology at University of California, San Diego, shares updates from ACG 2019 in the field of gastroenterology.

Cash talks ACG 2019 highlights and shares the findings of a poster presentation on a new bowel preparation for colonoscopy.

During the ACG meeting, investigators tested a subcutaneous form of vedolizumab to treat ulcerative colitis.

Miguel Regueiro, MD, of the Cleveland Clinic, talks about some of the medications that treat ulcerative colitis and Crohn's disease at the annual ACG meeting.

With the recent FDA approval, ustekinumab could be the first choice to treat ulcerative colitis.

Millie Long, MD, MPH, FACG, associate professor of medicine at the University of North Carolina, Chapel Hill, shares takeaways from a poster presentation at ACG 2019 on the use of day care and infectious complications in children born to mothers with inflammatory bowel disease.

In a study presented at the ACG 2019 meeting, investigators discuss their groundbreaking work on inflammatory bowel disease.

In a pioneer study, investigators investigate if cannabis users had less incidence of pancreatic necrosis and/or pancreatic/peripancreatic fluid collections.

Investigators test a subcutaneous version of vedolizumab for different durations to treat ulcerative colitis.

At the annual ACG meeting, Carlos Romero-Marrero, MD and Mohammad Alomari, MD discuss what can be done to reduce the drug use rate for high risk patients.

Stephen B. Hanauer, MD, discusses areas of unmet need in gastroenterology and shares what news made a splash at ACG 2019.

Millie Long, MD, MPH, FACG, shares initial updates from the ongoing TARGET-IBD study.

Brooks Cash, MD, delivers his take on areas of unmet need within the gastroenterology field.

Taha Qazi, MD, summarizes his research presented at ACG 2019 comparing objective sleep parameters in minority IBD patients compared to Caucasian IBD patients.

In a study presented at the annual ACG meeting, investigators find that 1L vedolizumab does not impact the effectiveness of subsequent anti-TNF treatment.

Philip Schoenfeld, MD, MSEd, MSc, discusses the benefits of quality indicators in colorectal cancer screening with colonoscopy.

In a poster presented at the annual ACG meeting, investigators estimate the prevalence of medication use by drug class for IBD-patients based on age.